Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease
Sponsor: Alnylam Pharmaceuticals
Summary
The purpose of this study is to: * Evaluate the safety and tolerability of intrathecal (IT) ALN-5288 in patients with Alzheimer's Disease (AD) * Evaluate the pharmacodynamic (PD) and pharmacokinetic (PK) effects of ALN-5288 after dose administration
Official title: A Phase 1, Randomized, Placebo-controlled Study With a Double Blind Period With Open-label Extension Period to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ALN-5288 in Adult Patients With Alzheimer's Disease
Key Details
Gender
All
Age Range
40 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2025-10-15
Completion Date
2030-03-06
Last Updated
2026-03-31
Healthy Volunteers
No
Conditions
Interventions
ALN-5288
ALN-5288 will be administered IT.
Placebo
Placebo will be administered IT.
Locations (6)
Clinical Trial Site
Montreal, Canada
Clinical Trial Site
Ottawa, Canada
Clinical Trial Site
Toronto, Canada
Clinical Trial Site
Toronto, Canada
Clinical Trial Site
Glasgow, United Kingdom
Clinical Trial Site
London, United Kingdom